Key Highlights
- Expanded license agreement: Base4 Biotechnology (formerly Nymirum) and Servier strengthen their strategic collaboration to accelerate neuroscience drug candidates development.
- Innovative DART Platform: Utilizes ensemble-based drug discovery, identifying druggable RNA regions, and screening novel compounds for therapeutic innovation.
- Commitment to neurological diseases: The partnership emphasizes a continued focus on addressing unmet medical needs in neuroscience, leveraging advanced RNA modulation techniques.
Source: PR Newswire
Notable Quotes
- “At Servier, we are always looking for ways to better help patients with unmet medical needs whether through internal or partnered research projects,” – Ross Jeggo, Global Head of Neuroscience and Immuno-Inflammation Therapeutic Area at Servier
- “We are happy to see the significant progress made by the Base4 and Servier teams,” – Joshua Fairbank, Chief Executive Officer and Co-Founder at Base4
SoH's Take
The expansion of the partnership between Base4 Biotechnology and Servier marks a significant step forward in the field of neuroscience drug development. Leveraging Base4’s DART Platform, this collaboration is set to pioneer the discovery and development of RNA-targeted small molecule therapeutics. The commitment to addressing the intricate challenges of neurological diseases through innovative RNA modulation signifies a promising horizon for patients with unmet medical needs. As the industry continues to recognize the potential of RNA as a therapeutic target, this partnership is well-positioned to lead transformative advances in medicine.
